Related Experiment Video

Updated: Jan 11, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

A Further Case for Targeting PRMT5 and the ERK1/2 and PI3K Pathways in CRC

Mark Spivak1, Moshe Pahmer2, Dorna Delrahimnia3

  • 1College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA.

International Journal of Molecular Sciences
|November 13, 2025
PubMed

Insights

Protein Arginine Methyltransferase 5 (PRMT5) is linked to key cancer pathways in colorectal cancer (CRC). Targeting PRMT5 and the ERK1/2 and PI3K pathways may offer new therapeutic strategies for CRC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Colorectal cancer (CRC) is a leading cause of cancer mortality.
  • Aberrant signaling through the ERK1/2 and PI3K pathways drives CRC progression and is linked to poor prognosis.
  • Protein Arginine Methyltransferase 5 (PRMT5) is an epigenetic regulator implicated in cancer, potentially modulating these pathways.

Purpose of the Study:

  • To investigate the relationship between PRMT5 and the ERK1/2 and PI3K pathways in colorectal cancer.
  • To provide further evidence supporting therapeutic strategies targeting PRMT5 in CRC.

Main Methods:

  • Analysis of patient tumor gene expression data.
  • Utilizing protein-protein interaction networks.

Main Results:

  • PRMT5 shows a positive correlation with the ERK1/2 and PI3K pathways in CRC.
  • Evidence of interaction between PRMT5 and these signaling pathways was identified.

Conclusions:

  • Findings strengthen the association between PRMT5 and key oncogenic pathways in CRC.
  • Further research into targeting PRMT5 and the ERK1/2/PI3K pathways for CRC treatment is warranted.
Keywords:
AKTCRCERKKRASMEKPI3KPRMT5PTENRAFmTOR

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.6K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

887

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K